VCA Stocks

Pieris AG, a biopharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, announced today the closing of a EUR 25 million (US$ 38 million) Series B financing round.  PRS-050 Anticalin® has been designed to specifically bind and block the signalling activity of vascular endothelial growth factor (VEGF) in cancer. Optimised for extended serum half-life, PRS-050 exhibits comparable binding and functional in vitro activity to approved VEGF antagonists. Potent inhibition of VEGF-induced enhanced vascular permeability and angiogenesis, as well as anti-tumour activity, have already been demonstrated for PRS-050 in various well-validated in vivo preclinical studies.